Cipla

Is Cipla overvalued or undervalued?

As of May 9, 2025, Cipla is considered undervalued with an attractive valuation grade, a PE Ratio of 22.99, and favorable comparisons to peers like Sun Pharma and Divi's Lab, despite recent stock performance lagging behind the Sensex, while showing strong growth potential with a 54.92% return over three years.

As of 9 May 2025, Cipla's valuation grade has moved from fair to attractive, indicating a positive shift in its perceived value. The company is currently considered undervalued. Key ratios include a PE Ratio of 22.99, an EV to EBITDA of 15.93, and a PEG Ratio of 0.97, which suggests that the stock is priced favorably relative to its growth potential.<BR><BR>In comparison to its peers, Cipla's valuation appears more appealing, especially when contrasted with Sun Pharma's PE Ratio of 35.25 and Divi's Lab's significantly high PE Ratio of 79.33. Additionally, Dr. Reddy's Labs, which is also rated attractive, has a lower PE Ratio of 19.49, further supporting the notion that Cipla is undervalued in its sector. While Cipla's recent stock performance has lagged behind the Sensex on a year-to-date basis, its strong return over three years at 54.92% reinforces its potential for growth.

Who are the top shareholders of the Cipla?

The top shareholders of Cipla include promoters, with Yusuf Khwaja Hameid holding 18.68%, institutional investors with mutual funds at 20.51% and foreign institutional investors at 26.28%, and individual shareholders who collectively own 14.13%. The largest public shareholder is the HDFC Large and Mid Cap Fund, holding 5.13%.

The top shareholders of Cipla include a mix of promoters, institutional investors, and individual shareholders. The majority shareholders are the promoters, with Yusuf Khwaja Hameid being the promoter with the highest holding at 18.68%. <BR><BR>In terms of institutional investments, mutual funds hold 20.51% of the shares through 42 schemes, while foreign institutional investors (FIIs) hold 26.28% through 980 different entities. The highest public shareholder is the HDFC Large and Mid Cap Fund, which holds 5.13%. Additionally, individual investors collectively hold 14.13% of the company's shares.

When is the next results date for Cipla?

No Upcoming Board Meetings

What does Cipla do?

Cipla Limited is a prominent Indian pharmaceutical company that manufactures and markets a variety of branded and generic drugs and Active Pharmaceutical Ingredients (APIs). As of March 2025, it reported net sales of ₹6,730 Cr and a net profit of ₹1,222 Cr, with a market cap of ₹121,226 Cr.

Overview: <BR>Cipla Limited is a leading pharmaceutical company in India, engaged in the manufacturing, developing, and marketing of a wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs) within the Pharmaceuticals & Biotechnology industry.<BR><BR>History: <BR>Cipla was incorporated in the year 1935. The latest quarterly results reported are for March 2025, showing net sales and profit figures.<BR><BR>Financial Snapshot: <BR>Net Sales: 6,730 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 1,222 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 121,226 Cr (Large Cap)<BR><BR>Key Metrics: <BR>P/E: 23.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.87% <BR>Debt-Equity: -0.25 <BR>Return on Equity: 16.90% <BR>Price to Book: 3.86 <BR><BR>Contact Details: <BR>Address: Cipla House Peninsula Buss Par, Ganpatrao Kadam Mg Lower Parel Mumbai Maharashtra : 400013 <BR>Tel: 91-22-24826000 <BR>Email: cosecretary@cipla.com <BR>Website: http://www.cipla.com

What is the bonus history of the Cipla?

Cipla's most recent bonus issue occurred on April 24, 2006, when the company announced a 3:2 bonus, granting shareholders three shares for every two held, with a record date of April 25, 2006.

Cipla has a bonus history that includes a notable issuance on April 24, 2006. During this event, the company announced a 3:2 bonus issue, which means that for every two shares held, shareholders received three shares. The record date for this bonus was April 25, 2006. This was the latest bonus action recorded for Cipla. If you have any more questions about the company or its financials, feel free to ask!

Has Cipla declared dividend?

Cipla Ltd. has declared a 650% dividend, with an ex-date of June 27, 2025. The company has shown strong total returns over various periods, including a 134.92% total return over the past 5 years.

Cipla Ltd. has declared a 650% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 650%<BR>- Ex-date: 27 Jun 25<BR><BR>Dividend Yield: 0.87%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, Cipla experienced a price return of 1.37%, with no dividend return, resulting in a total return of 1.37%.<BR><BR>Over the past year, the price return was 1.39%, with a dividend return of 0.85%, leading to a total return of 2.24%.<BR><BR>In the 2-year period, Cipla saw a significant price return of 54.06% and a dividend return of 2.13%, culminating in a total return of 56.19%.<BR><BR>For the 3-year period, the price return was 53.43% with a dividend return of 2.89%, resulting in a total return of 56.32%.<BR><BR>In the last 4 years, the company achieved a price return of 58.24% and a dividend return of 3.27%, leading to a total return of 61.51%.<BR><BR>Over the past 5 years, Cipla reported a remarkable price return of 130.04% along with a dividend return of 4.88%, resulting in a total return of 134.92%.<BR><BR>Overall, Cipla has declared a substantial dividend and has shown strong total returns over various periods, indicating a positive performance trend for the company.

Who are the peers of the Cipla?

Cipla's peers include Sun Pharma, Divi's Lab, Torrent Pharma, Dr Reddy's Labs, Mankind Pharma, Zydus Lifesciences, Lupin, Aurobindo Pharma, Abbott India, and Alkem Lab. Divi's Lab has the highest 1-year return at 51.96%, while Aurobindo Pharma has the lowest at -6.51%, with Cipla's return at 0.86%.

Peers: Cipla's peers include Sun Pharma.Inds., Divi's Lab., Torrent Pharma, Dr Reddy's Labs, Mankind Pharma, Zydus Lifesci., Lupin, Aurobindo Pharma, Abbott India, and Alkem Lab.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Mankind Pharma, Zydus Lifesci., Aurobindo Pharma, Abbott India, and Alkem Lab, while Average management risk is found at Lupin. Growth is excellent for Sun Pharma.Inds., Cipla, Dr Reddy's Labs, Mankind Pharma, Zydus Lifesci., and Lupin, while below average growth is noted for Divi's Lab., Torrent Pharma, Aurobindo Pharma, and Alkem Lab, and the rest. Excellent capital structure is seen in Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs., Mankind Pharma, Zydus Lifesci., and Aurobindo Pharma, while good capital structure is observed at Torrent Pharma and Lupin, and the rest.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.96%, while Aurobindo Pharma has the lowest at -6.51%. Cipla's own 1-year return is 0.86%, which is lower than Divi's Lab. and higher than Aurobindo Pharma. Additionally, the six-month returns for Torrent Pharma, Mankind Pharma, Zydus Lifesci., Aurobindo Pharma, and Alkem Lab are negative.

Who are in the management team of Cipla?

As of March 2023, Cipla's management team includes Y K Hamied (Chairman), M K Hamied (Vice Chairman), Umang Vohra (Managing Director & Global CEO), and several independent directors, bringing diverse expertise to the company.

As of March 2023, the management team of Cipla includes the following individuals:<BR><BR>1. Y K Hamied - Chairman (Non-Executive)<BR>2. M K Hamied - Vice Chairman<BR>3. S Radhakrishnan - Non-Executive & Non-Independent Director<BR>4. Ashok Sinha - Non-Executive & Independent Director<BR>5. Peter Mugyenyi - Non-Executive & Independent Director<BR>6. Adil Zainulbhai - Non-Executive & Independent Director<BR>7. Punita Lal - Non-Executive & Independent Director<BR>8. Samina Hamied - Executive Vice Chairperson<BR>9. Umang Vohra - Managing Director & Global CEO<BR>10. Rajendra Chopra - Company Secretary & Compliance Officer<BR>11. Robert A Stewart - Independent Director<BR>12. P R Ramesh - Independent Director<BR>13. Mandar Purushottam Vaidya - Independent Director<BR><BR>This diverse team brings a wealth of experience and expertise to the company.

How big is Cipla?

As of 24th July, Cipla Ltd. has a market capitalization of 119,313.00 Cr, with recent Net Sales of 27,547.62 Cr and a Net Profit of 5,272.52 Cr. The company reported Shareholder's Funds of 31,193.45 Cr and Total Assets of 36,742.17 Cr.

As of 24th July, Cipla Ltd. has a market capitalization of 119,313.00 Cr, categorizing it as a Large Cap company.<BR><BR>In the latest four quarters, Cipla reported Net Sales of 27,547.62 Cr and a Net Profit of 5,272.52 Cr.<BR><BR>For the latest annual period, the company reported Shareholder's Funds of 31,193.45 Cr and Total Assets of 36,742.17 Cr.

How has been the historical performance of Cipla?

Cipla has demonstrated strong financial growth, with net sales increasing from 19,159.59 Cr in Mar'21 to 27,547.62 Cr in Mar'25, and profit after tax rising from 1,546.98 Cr to 5,291.05 Cr during the same period. Key metrics such as operating profit and earnings per share also showed significant improvement, reflecting robust profitability and operational efficiency.

Answer:<BR>Cipla has shown a consistent growth trajectory in its financial performance over the years, with net sales increasing from 19,159.59 Cr in Mar'21 to 27,547.62 Cr in Mar'25. The total operating income followed a similar upward trend, reaching 27,547.62 Cr in Mar'25 from 19,159.59 Cr in Mar'21. The operating profit (PBDIT) also saw significant growth, climbing to 7,989.77 Cr in Mar'25 from 3,550.19 Cr in Mar'20. Profit before tax rose to 6,820.81 Cr in Mar'25, up from 2,178.18 Cr in Mar'20, while profit after tax reached 5,291.05 Cr in Mar'25, compared to 1,546.98 Cr in Mar'20. The earnings per share (EPS) improved markedly, standing at 65.29 in Mar'25, up from 19.18 in Mar'20. <BR><BR>On the balance sheet side, total assets increased from 23,422.79 Cr in Mar'20 to 36,742.17 Cr in Mar'25, with total liabilities also rising from 23,422.79 Cr to 36,742.17 Cr during the same period. Shareholder's funds grew from 15,763.00 Cr in Mar'20 to 31,193.45 Cr in Mar'25, indicating a strengthening equity position. The cash flow from operating activities improved to 5,004.00 Cr in Mar'25 from 3,068.00 Cr in Mar'20, while net cash inflow turned positive at 30.00 Cr in Mar'25, contrasting with negative outflows in previous years. Overall, Cipla's financial metrics reflect a robust growth pattern and improved profitability over the analyzed period. <BR><BR>Breakdown:<BR>Cipla's financial performance has demonstrated a strong upward trend across multiple key metrics. Net sales surged from 19,159.59 Cr in Mar'21 to 27,547.62 Cr in Mar'25, while total operating income mirrored this growth, reaching the same figure in Mar'25. Operating profit (PBDIT) rose significantly from 3,550.19 Cr in Mar'20 to 7,989.77 Cr in Mar'25, showcasing improved operational efficiency. Profit before tax increased from 2,178.18 Cr in Mar'20 to 6,820.81 Cr in Mar'25, and profit after tax followed suit, climbing to 5,291.05 Cr from 1,546.98 Cr in Mar'20. The earnings per share (EPS) also saw a remarkable rise, reaching 65.29 in Mar'25, up from 19.18 in Mar'20. <BR><BR>On the balance sheet, total assets grew from 23,422.79 Cr in Mar'20 to 36,742.17 Cr in Mar'25, with total liabilities increasing in tandem. Shareholder's funds strengthened significantly, rising from 15,763.00 Cr to 31,193.45 Cr over the same period. Cash flow from operating activities improved to 5,004.00 Cr in Mar'25, compared to 3,068.00 Cr in Mar'20, and net cash inflow turned positive at 30.00 Cr in Mar'25, contrasting with negative figures in prior years. This overall performance indicates a solid growth trajectory and enhanced profitability for Cipla.

Is Cipla technically bullish or bearish?

As of December 1, 2025, Cipla's technical trend has shifted to sideways, with mixed indicators showing a mildly bearish MACD, bullish weekly RSI, and conflicting signals from moving averages and Bollinger Bands, indicating a lack of clear direction.

As of 1 December 2025, the technical trend for Cipla has changed from mildly bullish to sideways. The current technical stance is neutral, with mixed indicators influencing the outlook. The MACD is mildly bearish on both the weekly and monthly time frames, while the RSI shows bullish momentum on the weekly but no signal on the monthly. Moving averages indicate a mildly bullish trend on the daily, contrasting with the bearish signals from Bollinger Bands and KST on the weekly. Dow Theory reflects a mildly bearish stance on the weekly and no trend on the monthly. Overall, the mixed signals suggest a lack of clear direction, reinforcing the sideways trend.

Are Cipla Ltd. latest results good or bad?

Cipla Ltd.'s latest results show a 7.64% revenue growth, but significant contraction in operating margins and a bearish stock outlook suggest more concerns than positives, indicating a cautious approach for investors.

Cipla Ltd.'s latest results present a mixed picture. On one hand, the company reported a healthy revenue growth of 7.64% year-on-year, with net sales reaching ₹7,589.44 crores. This indicates that the company is still able to generate increasing sales. However, the operating margins have contracted significantly, dropping to 25.44% from 26.01% in the previous quarter, which raises concerns about operational efficiency and cost pressures.<BR><BR>Net profit for the quarter was ₹1,351 crores, reflecting a modest increase of 4.13% quarter-on-quarter, but this growth is slower compared to revenue growth, indicating potential challenges in translating sales into profit. Furthermore, the stock has entered a bearish technical trend, and the proprietary advisory score has been downgraded to 36 out of 100, suggesting a "SELL" rating.<BR><BR>Overall, while the revenue growth is a positive sign, the significant contraction in operating margins and the bearish outlook on the stock suggest that the results are more concerning than favorable. Investors may want to approach with caution given the current operational challenges and market sentiment.

Should I buy, sell or hold Cipla Ltd.?

Why is Cipla Ltd. falling/rising?

As of 17-Mar, Cipla Ltd.'s stock price is declining, currently at 1,281.45, reflecting a 1.34% decrease and reaching a new 52-week low. The stock has underperformed its sector and has seen a significant drop in financial performance, contributing to investor caution and a bearish trend.

As of 17-Mar, Cipla Ltd.'s stock price is falling, currently at 1,281.45, which reflects a decrease of 17.35 or 1.34%. The stock has been on a downward trend, having lost 3.87% over the past week and 4.61% over the past month. Notably, it has reached a new 52-week low of Rs. 1275.65 today. The stock has underperformed its sector by 1.62% and has been declining for five consecutive days.<BR><BR>Several factors contribute to this decline. The stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. Additionally, there has been a decrease in investor participation, with delivery volume falling by 11.28% compared to the 5-day average. <BR><BR>Financial performance has also been disappointing, with a significant drop in profit before tax (PBT) and profit after tax (PAT) reported in the latest quarter, both falling by around 35% compared to the previous four-quarter average. Over the past year, while the stock has generated a return of -14.17%, its profits have decreased by 4.7%. This underperformance is further highlighted by the stock's negative returns compared to the broader market, as it has lagged behind the BSE500 over various time frames.<BR><BR>Despite some positive long-term growth indicators, such as a healthy annual growth rate in net sales and operating profit, the recent financial results and ongoing decline in stock performance suggest that investors are currently cautious, leading to the stock's downward movement.

Why is Cipla Ltd. falling/rising?

As of 18-Mar, Cipla Ltd.'s stock price is declining, currently at 1,268.20, marking a 4.87% drop over the last six days and reaching a new 52-week low. The stock has underperformed its sector and reported a significant profit decline, contributing to a bearish trend despite some positive long-term metrics.

As of 18-Mar, Cipla Ltd.'s stock price is falling, currently at 1,268.20, reflecting a decrease of 13.25 (-1.03%). The stock has been on a downward trend, having lost value for the last six consecutive days, resulting in a total decline of 4.87% during this period. Additionally, the stock has underperformed its sector by 1.3% today and has reached a new 52-week low of Rs. 1265.<BR><BR>In terms of performance metrics, Cipla's stock has shown negative returns over various time frames, including a 1-week decline of 4.64%, a 1-month drop of 6.00%, and a year-to-date decrease of 16.06%. Over the past year, the stock has generated a return of -15.94%, while its profits have fallen by 4.7%. This underperformance is compounded by the fact that the stock is trading below its moving averages across multiple time frames, indicating a bearish trend.<BR><BR>Moreover, the company has reported disappointing financial results, with a significant drop in profit after tax of 35.0% compared to the previous quarter's average. The low cash and cash equivalents, along with a below-par performance in both the long term and near term, further contribute to the negative sentiment surrounding the stock. Despite having a low debt-to-equity ratio and healthy long-term growth in net sales and operating profit, these factors have not been sufficient to counteract the current downward pressure on the stock price.

Why is Cipla Ltd. falling/rising?

As of 19-Mar, Cipla Ltd. is facing a stock price decline to 1,244.85, down -1.84%, with a total drop of -6.62% over the past week and a new 52-week low of Rs. 1235.8. The stock has underperformed against the Sensex and shows a bearish trend, compounded by negative profit results and broader sector declines.

As of 19-Mar, Cipla Ltd. is experiencing a decline in its stock price, currently at 1,244.85, which reflects a change of -23.35 (-1.84%). This downward movement is attributed to several factors. The stock has been on a consecutive fall for the last seven days, resulting in a total decline of -6.62% during this period. Additionally, it hit a new 52-week low of Rs. 1235.8 today, indicating significant selling pressure.<BR><BR>In terms of performance relative to the market, Cipla has underperformed compared to the Sensex, with a one-week decline of -6.07% against the Sensex's -2.40%. Over the past year, the stock has generated a return of -16.93%, while its profits have decreased by -4.7%. This poor performance is compounded by negative results reported in December, where both profit before tax and profit after tax fell significantly compared to previous quarters.<BR><BR>Moreover, Cipla is trading below its moving averages across various time frames, which typically signals a bearish trend. The broader Pharmaceuticals & Drugs sector has also seen a decline of -2.11%, contributing to the negative sentiment surrounding the stock. Despite some positive indicators, such as rising investor participation and a low debt-to-equity ratio, the overall outlook remains weak, leading to the stock's current downward trajectory.

Why is Cipla Ltd. falling/rising?

As of 20-Mar, Cipla Ltd. is seeing a stock price increase to 1,260.65, following a trend reversal after a decline, but it has underperformed year-to-date and over the past year. Despite a recent uptick, declining investor participation and negative financial results may continue to affect investor confidence.

As of 20-Mar, Cipla Ltd. is experiencing a rise in its stock price, currently at 1,260.65, reflecting an increase of 22.0 (1.78%). This upward movement follows a trend reversal after seven consecutive days of decline, indicating a potential shift in investor sentiment. The stock reached an intraday high of Rs 1264, which is a 2.05% increase from its previous close.<BR><BR>Despite this recent uptick, the stock has been underperforming over longer periods, with a year-to-date decline of 16.56% and a one-year drop of 16.68%. The stock is also trading lower than its moving averages across various time frames, suggesting that it has not maintained consistent upward momentum. Additionally, there has been a significant decrease in investor participation, with delivery volume falling by 47.92% compared to the five-day average, which may indicate waning interest among retail investors.<BR><BR>On a positive note, Cipla Ltd. has a low debt-to-equity ratio and has shown healthy long-term growth in net sales and operating profit. The stock is trading at a discount compared to its peers, and high institutional holdings at 54.66% suggest that more sophisticated investors are backing the company. However, the recent negative financial results, including a substantial decline in profit before tax and profit after tax, have contributed to the stock's overall poor performance in the past year, which may still weigh on investor confidence despite the recent price increase.

Which are the latest news on Cipla?

Which are the latest news on Cipla?

Which are the latest news on Cipla?